首页> 外文期刊>Drug development and industrial pharmacy >In vitro evaluation of compression-coated glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu2+)-loaded microparticles for colonic drug delivery.
【24h】

In vitro evaluation of compression-coated glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu2+)-loaded microparticles for colonic drug delivery.

机译:压缩涂层的巯基-L-组氨酸-L-赖氨酸-Cu(II)(GHK-Cu2 +)负载微粒的体外评估,用于结肠给药。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu(2+))-loaded Zn-pectinate microparticles in the form of hydroxypropyl cellulose (HPC) compression-coated tablets were prepared and their in vitro behavior tested. GHK-Cu(2+) delivery to colon can be useful for the inhibition of matrix metalloproteinase, with the increasing secretion of tissue inhibitors of metalloproteinases (TIMPS),which are the major factors contributing in mucosal ulceration and inflammation in inflammatory bowel disease. The concentration of peptide was determined spectrophotometrically. The results obtained implied that surfactant ratio had a significant effect on percent production yield (1.25 to 1.75 w/w; 72.22% to 80.84%), but cross-linking agent concentration had not. The entrapment efficiency (EE) was found to be in the range of 58.25-78.37%. The drug-loading factor significantly increased the EE; however, enhancement of cross-linking agent concentration decreased it. The release of GHK-Cu(2+) from Zn-pectinate microparticles (F1-F8) in simulated intestinal fluid was strongly affected by cross-linking agent concentration and drug amount (50 mg for F1-F6; 250 mg for F7-F8), but not particularly affected by surfactant amount. Release profiles represented that the microparticles released 50-80% their drug load within 4 h. Therefore, the optimum microparticle formulation (F8) coated with a relatively hydrophobic polymer HPC to get a suitable colonic delivery system. The optimum colonic delivery tablets prepared with 700 mg HPC-SL provided the expected delayed release with a lag time of 6 h. The effects of polymer viscosity and coat weight on GHK-Cu(2+) release were found to be crucial for the optimum delay of lag time. The invention was found to be promising for colonic delivery.
机译:制备了以羟丙基纤维素(HPC)压片形式的负载甘氨酰-L-组氨酸-L-赖氨酸-Cu(II)(GHK-Cu(2+))的果胶酸锌果胶微粒,并测试了其体外行为。 GHK-Cu(2+)传递到结肠可用于抑制基质金属蛋白酶,增加金属蛋白酶组织抑制剂(TIMPS)的分泌,这是促炎性肠病的粘膜溃疡和炎症的主要因素。分光光度法测定肽的浓度。所得结果表明表面活性剂比例对产率百分率有显着影响(1.25至1.75w / w; 72.22%至80.84%),但是交联剂浓度没有。发现包封率(EE)为58.25-78.37%。载药因子显着提高了EE;然而,交联剂浓度的增加降低了交联剂的浓度。 GHK-Cu(2+)在模拟肠液中从果胶锌微粒(F1-F8)中的释放受到交联剂浓度和药物用量的强烈影响(F1-F6为50 mg; F7-F8为250 mg ),但不受表面活性剂用量的特别影响。释放曲线表明,微粒在4小时内释放了50-80%的药物负荷。因此,用相对疏水的聚合物HPC涂覆的最佳微粒制剂(F8)可获得合适的结肠递送系统。用700 mg HPC-SL制备的最佳结肠递送片剂可提供预期的延迟释放,滞后时间为6小时。发现聚合物粘度和涂层重量对GHK-Cu(2+)释放的影响对于最佳延迟时间至关重要。发现本发明有望用于结肠递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号